We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 606

FDA launches openFDA database with reports on prescription drug side effects
  • Shook Hardy & Bacon LLP
  • USA
  • June 12 2014

The U.S. Food and Drug Administration (FDA) has launched a database that pulls together large amounts of data to enable "those in private and public


Biotech secures $5.3 million for immunosuppressant drug research
  • Shook Hardy & Bacon LLP
  • USA
  • April 18 2013

San Francisco-based startup, Nurix, Inc., which reportedly develops T-cellspecific immunosuppressants used to treat autoimmune diseases such as


Biopharmaceutical sets $150-million IPO terms
  • Shook Hardy & Bacon LLP
  • USA
  • November 21 2013

According to a news source, Redwood City, California-based Relypsa, Inc. seeks to raise $150 million by offering more than 7.87 million shares priced


Compounding-pharmacy legislation awaits President’s signature
  • Shook Hardy & Bacon LLP
  • USA
  • November 21 2013

The U.S. Senate has approved by voice vote a bill (H.R. 3204) that would broaden federal oversight of compounding pharmacies; it now awaits President


U.S. nonprofit helps fund search for DMD cure
  • Shook Hardy & Bacon LLP
  • Netherlands, USA
  • August 21 2014

According to a news source, CureDuchenne, a U.S. national nonprofit seeking a cure for Duchenne Muscular Dystrophy (DMD), will provide up to 5


Vaccine developer agrees to settle shareholder litigation
  • Shook Hardy & Bacon LLP
  • USA
  • September 11 2014

A putative class action instituted by three shareholders against the nowbankrupt biotechnology company Biovest International, Inc., alleging


Takeda acquires access to Envoy’s CNS drug pipeline and bacTRAP technology
  • Shook Hardy & Bacon LLP
  • USA
  • November 15 2012

Takeda America Holdings, Inc. has reportedly acquired Envoy Therapeutics, Inc. in a deal worth $140 million, including an up-front payment and progressdependent milestone payments


Federal Circuit’s patent infringement ruling conflicts with USPTO re-examination on validity
  • Shook Hardy & Bacon LLP
  • USA
  • November 1 2012

The Federal Circuit Court of Appeals has denied a request for an en banc rehearing by a medical-device patent holder which argued that the U.S. Patent and Trademark Office’s (USPTO’s) Board of Patent Appeals had effectively nullified a previous Federal Circuit decision on the validity of its patent


Gelesis raises $12 million to advance obesity pill
  • Shook Hardy & Bacon LLP
  • USA
  • May 22 2014

Weight-loss treatment developer Gelesis, Inc. has completed a $12-million financing round. Led by PureTech, which founded Gelesis in 2006, and the


Biotech company settles claims that counsel divulged confidential information
  • Shook Hardy & Bacon LLP
  • USA
  • April 21 2011

A federal court in California has dismissed with prejudice claims that a biotech company filed against its former counsel alleging that the law firm had provided confidential information about the company's patent applications to another client